The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.
about
New era of biologic therapeutics in atopic dermatitisComparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort studyPattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank.Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trialTwo additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.Signal pathways JNK and NF-kappaB, identified by global gene expression profiling, are involved in regulation of TNFalpha-induced mPGES-1 and COX-2 expression in gingival fibroblasts.Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cellsEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsTime trends in the characteristics of patients undergoing primary total knee arthroplasty.Evaluation of the anti-arthritic activity of the hydroethanolic leaf extract of Alchornea cordifolia in rats.Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.Applying science in practice: the optimization of biological therapy in rheumatoid arthritis.Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trendsEconomic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesPredictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease.TNF-induced structural joint damage is mediated by IL-1.Are biological agents toxic to human chondrocytes and osteocytes?Sex Differences in the Effects of a Biological Drug for Rheumatoid Arthritis on Depressive StateDecision tool to improve the quality of care in rheumatoid arthritisInvestigating endogenous peptides and peptidases using peptidomicsCells of the synovium in rheumatoid arthritis. Macrophages.A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis.Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohortBiological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Abatacept in difficult-to-treat juvenile idiopathic arthritis.Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice.Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists.A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.Sensing damage by the NLRP3 inflammasome.Interleukin-6 inhibitors in the treatment of rheumatoid arthritis.Exploring interaction of TNF and orthopoxviral CrmB protein by surface plasmon resonance and free energy calculation.Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.Evaluation of analgesic and anti-inflammatory activity of Bridelia retusa (Spreng) barkMethodological issues in the design of a rheumatoid arthritis activity score and its cut-offs.
P2860
Q27001941-A6DDD312-29F7-45D6-9AFB-72B1B26EF99DQ28542423-3BFBA4E8-BB63-40B8-9378-F36B4AE170E1Q33451953-5B4E0C36-ACFE-4806-8F51-8D3662E58C1DQ33470696-4FFB2EDB-382D-4C97-82A0-607CE73E7ECAQ33540867-89D68C37-1305-4B38-A09C-C8A353666A12Q33557663-1339B607-7080-4021-9362-37EB47176FF1Q33973884-70A20FC6-8801-4ED7-B1A9-FAFF1515F2AEQ34011616-00366FD8-2750-446B-919C-5EEB8541BB31Q34110066-E7F68276-0699-4EB6-BF5F-E527096928FFQ34118945-8B071DCF-E712-460C-9609-1D652C36F124Q34368487-561EA91B-9A92-4F71-AF78-FF7F7664D98DQ34495874-1D48C74E-784C-4A87-AFA6-25AC913B9B3DQ34613898-58534B9C-7761-4670-A700-8420D33FD118Q34996439-2E6CDFDD-31BD-430B-9A6D-0CBCE00DAE39Q35001257-4CDBDADA-7582-4A90-80E6-E290E816FC03Q35048347-47D5D580-8ED5-438A-95BE-EABA721C3E57Q35133812-C68F0061-CBA0-45A6-A3E9-43CC3C3100DFQ35577993-C84B1C21-4771-43CC-831C-4CC6AFA2A65AQ35880188-4C19ACD2-368D-4CAB-870C-E157101C0FEAQ35903134-8EF2DE4D-BD60-420B-BE85-28F99FA158E9Q35970365-82EB0312-6384-4849-B6C0-9B8B4627F08EQ36032715-E2DB0F18-3B0A-4E1E-A99F-D72F47BEC9C5Q36163374-888A827D-1DD6-4C5F-A1C3-7E61823E6B8AQ36465497-0F0C442B-A4EA-48F2-BD5C-68073202CFFCQ36735853-9B3F6FAF-8F53-4E08-9636-7F43EA1A219CQ36790391-403294D0-4258-4FCD-A8C9-BF87972BF064Q36961298-E81F8E80-FB5D-4DE8-9A9C-52AE59F5C847Q37009469-5E72304E-134A-4923-B4FE-31E5CD30DEE8Q37129582-6750F19B-12A5-4D13-95AC-F0357A77DBABQ37290665-31C9B798-1F81-4794-A075-CEE24DFE3AA3Q37307846-CCDB3A3A-FBCF-4090-A73B-771E47E17E6CQ37326948-DDC0559E-FA0A-400B-848F-C686B594D34BQ37355624-00CA86EB-B39A-4EE0-88C2-CD3A0DB00917Q37428436-F1B7FFBF-7F9C-43CA-8261-7A05C862C472Q37925073-9341BA79-FCAB-4FEC-BB29-88FF889092D8Q40003399-06BE83E7-81A4-4E8D-8696-5DAAF21CCDB9Q41142790-40EE7EBD-EF55-44BD-9706-4DBA553413D7Q42146734-2A6C4C53-9DE4-480E-8A30-6690063EC399Q42374035-F91F206C-F29B-4E04-A02C-6FFEB8BBB184Q42734608-DD2E5E87-79B3-4D60-A2ED-CD016CB73151
P2860
The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The comparative efficacy and s ...... matic review and metaanalysis.
@ast
The comparative efficacy and s ...... matic review and metaanalysis.
@en
type
label
The comparative efficacy and s ...... matic review and metaanalysis.
@ast
The comparative efficacy and s ...... matic review and metaanalysis.
@en
prefLabel
The comparative efficacy and s ...... matic review and metaanalysis.
@ast
The comparative efficacy and s ...... matic review and metaanalysis.
@en
P2093
P1476
The comparative efficacy and s ...... ematic review and metaanalysis
@en
P2093
Beth L Jonas
Kathleen N Lohr
Patricia Thieda
Richard A Hansen
P304
P407
P577
2006-12-01T00:00:00Z